Topical Bimatoprost for Chemical Blepharoplasty
Completed · Early Phase 1
Conditions studied: Dermatochalasis
In brief
Topical bimatoprost has been shown to cause periorbital changes of soft tissue which are most pronounced when used directly onto the cornea for the treatment of glaucoma. Changes are primarily felt to be the result of prostaglandin-mediated adipocyte loss, resulting in deepening of the upper eyelid sulcus and recession of infraorbital pseudoherniation. Use of topical bimatoprost to the upper eyelid margin, now FDA approved for eyelash enhancement, may provide a metered effect on the periocular tissues and allow for a topical approach to periocular rejuvenation. This is a proof of concept study which aims to enroll a series of patients with mild to severe dermatochalasis, treat with topical bimatoprost 0.03% solution to the upper lid margin, and evaluate for cosmetic improvement of the periocular area.
Key facts
- Study ID
- NCT02830776
- Run by
- Tulane University
- People needed
- 15
- Starts
- 2016-11-01
- Expected to finish
- 2017-06-30
- Last updated by the study team
- 2021-03-05
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- 18+,
- mild to severe dermatochalasis, desire for enhanced eyelashes.
You may not qualify if…
- Patients with current use of ophthalmic prostaglandin analogues,
- history of blepharoplasty,
- history of neuromodulators or fillers to the periocular region or frontalis in the last 6 months,
- existing deep upper eyelid sulcus,
- opposition to eyelash enhancement,
- pregnancy.
Where it is running
- Tulane Department of Dermatology — New Orleans, Louisiana, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.